HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), has signed a non-binding Letter of Intent to acquire Interventional Psychiatry Clinics in Florida. The target clinics are described as top performers, currently generating revenue and positive EBITDA. The acquisition is expected to be immediately accretive to both revenue and EBITDA for HOPE and NRx. These facilities will serve as the foundation for HOPE's expansion in Florida, offering comprehensive mental health services. The company aims to establish HOPE as a model for clinics providing the latest standard of care treatments for CNS healthcare providers nationwide.
HOPE Therapeutics, una sussidiaria di NRx Pharmaceuticals (Nasdaq: NRXP), ha firmato una Lettera d'Intenti non vincolante per acquisire le Cliniche di Psichiatria Interventistica in Florida. Le cliniche target sono descritte come straordinariamente performanti, generando attualmente ricavi e un EBITDA positivo. Si prevede che l'acquisizione sarà immediatamente accrescitiva sia per i ricavi che per l'EBITDA di HOPE e NRx. Queste strutture serviranno come base per l'espansione di HOPE in Florida, offrendo servizi completi di salute mentale. L'azienda mira a stabilire HOPE come un modello per le cliniche che forniscono i trattamenti più recenti per gli operatori sanitari nel settore CNS a livello nazionale.
HOPE Therapeutics, una subsidiaria de NRx Pharmaceuticals (Nasdaq: NRXP), ha firmado una Carta de Intención no vinculante para adquirir las Clínicas de Psiquiatría Intervencionista en Florida. Las clínicas objetivo se describen como de alto rendimiento, generando actualmente ingresos y un EBITDA positivo. Se espera que la adquisición tenga un efecto inmediato y positivo tanto en los ingresos como en el EBITDA para HOPE y NRx. Estas instalaciones servirán como la base para la expansión de HOPE en Florida, ofreciendo servicios integrales de salud mental. La compañía tiene como objetivo establecer HOPE como un modelo para clínicas que proporcionen los tratamientos más avanzados para los proveedores de salud CNS en todo el país.
HOPE Therapeutics는 NRx Pharmaceuticals(Nasdaq: NRXP)의 자회사로서 플로리다의 개입 정신과 클리닉을 인수하기 위한 비구속적 의향서를 체결했습니다. 목표 클리닉은 현재 수익과 긍정적인 EBITDA를 생성하며 최고 성과를 내는 곳으로 묘사됩니다. 이 인수는 HOPE와 NRx의 수익 및 EBITDA에 즉각적으로 긍정적인 기여를 할 것으로 예상됩니다. 이러한 시설들은 플로리다에서 HOPE의 확장을 위한 기초가 되며, 포괄적인 정신 건강 서비스를 제공할 것입니다. 이 회사는 HOPE를 전국적으로 CNS 의료 제공자를 위한 최신 치료 기준을 제공하는 클리닉 모델로 설정하는 것을 목표로 하고 있습니다.
HOPE Therapeutics, une filiale de NRx Pharmaceuticals (Nasdaq: NRXP), a signé une lettre d'intention non contraignante pour acquérir les cliniques de psychiatrie interventionnelle en Floride. Les cliniques ciblées sont décrites comme des performers de premier plan, générant actuellement des revenus et un EBITDA positif. On s'attend à ce que l'acquisition soit immédiatement bénéfique tant pour les revenus que pour l'EBITDA de HOPE et NRx. Ces établissements serviront de base à l'expansion de HOPE en Floride, offrant des services complets de santé mentale. L'entreprise vise à établir HOPE comme un modèle pour les cliniques fournissant les derniers traitements de norme de soins pour les prestataires de santé CNS à l'échelle nationale.
HOPE Therapeutics, eine Tochtergesellschaft von NRx Pharmaceuticals (Nasdaq: NRXP), hat ein nicht verbindliches Absichtsschreiben zur Übernahme der Interventionellen Psychiatriekliniken in Florida unterzeichnet. Die Zielkliniken werden als Spitzenreiter beschrieben und generieren derzeit Einnahmen sowie ein positives EBITDA. Man erwartet, dass die Übernahme sowohl für die Einnahmen als auch für das EBITDA von HOPE und NRx sofort positiv auswirkt. Diese Einrichtungen werden als Grundlage für die Expansion von HOPE in Florida dienen und umfassende psychische Gesundheitsdienste anbieten. Das Unternehmen strebt an, HOPE als Modell für Kliniken zu etablieren, die die neuesten Behandlungsstandards für CNS-Gesundheitsdienstleister im ganzen Land anbieten.
- Acquisition targets are currently revenue generating and EBITDA positive
- Deal expected to be immediately accretive to revenue and EBITDA
- Strategic expansion into Florida market with established clinics
- Letter of Intent is non-binding, indicating deal uncertainty
- Financial terms and acquisition costs not disclosed
Insights
The acquisition of revenue-generating and EBITDA-positive psychiatric clinics in Florida represents a significant strategic move for NRXP, a micro-cap company with a market cap of
The immediate accretive nature to both revenue and EBITDA is particularly noteworthy for a company of this size. The mental health sector has seen substantial growth, with interventional psychiatry clinics typically generating strong margins. However, investors should note that this is currently a non-binding LOI and final terms, including purchase price and financing details, are yet to be disclosed. The acquisition's success will largely depend on post-merger integration and the ability to maintain operational efficiency while scaling the clinical network.
The strategic acquisition of established Florida clinics positions HOPE Therapeutics advantageously in the rapidly growing interventional psychiatry market. Florida's demographics, with its large elderly population and increasing mental health awareness, present significant growth opportunities. The focus on clinics that are already operational and profitable reduces execution risk compared to greenfield expansion.
The mental health treatment market is experiencing a paradigm shift toward interventional approaches, with increasing insurance coverage and patient demand. This acquisition could serve as a blueprint for HOPE's national expansion strategy, potentially creating a scalable model for future clinic acquisitions. The emphasis on "intelligent and compassionate operations" suggests a focus on quality care delivery, which is important for long-term success in this sector.
- The clinics are located in favorable locations, are revenue generating and EBITDA positive
- Clinics offer a comprehensive range of mental health services
- Acquisition is expected to be immediately accretive to revenue and EBITDA for HOPE and NRx
The clinics to be acquired are revenue generating and EBITDA positive, thus the acquisition is expected to be immediately accretive to both revenue and EBITDA for HOPE and NRx.
"These clinics come to us highly recommended by industry insiders, and we have been impressed with their intelligent and compassionate operations," said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics. "Additionally, we look forward to working with the founders to help optimize additional acquisitions as they enter our network. This is another important step forward as we move to establish HOPE as a model for clinics that aim to provide the latest standard of care treatments for CNS healthcare providers nationwide."
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACT:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-signing-of-a-letter-of-intent-to-acquire-its-first-florida-interventional-psychiatry-clinics-302291284.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What clinics is NRXP acquiring in Florida?
Is the NRXP Florida clinic acquisition final?
How will the Florida clinic acquisition impact NRXP's financials?
What is NRXP's expansion strategy in Florida?
